Experimental IL-2 treatment shows promise for Hard-to-Treat HCV vasculitis
NCT ID NCT00574652
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called interleukin-2 (IL-2) in 10 people with hepatitis C-related vasculitis that did not get better with usual treatments. The goal was to see if IL-2 could boost the body's immune regulation and control the disease. Participants received IL-2 injections for several weeks, and researchers monitored immune responses and side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Interleukin-2 (IL-2, also called Proleukin or Aldesleukin)
- What this could lead to
- If it works, this could point toward a new treatment option for people with HCV-related vasculitis who do not respond to standard therapies.
- What could go wrong
- This was a very small, early-phase trial with only 10 participants, so results may not apply to everyone. The treatment may not be effective or could cause side effects like vasculitis flares.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CRYOGLOBULINEMIA VASCULITIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hôpital de la Pitié
Paris, 75651, France